Activating BRAF V600E mutation in aggressive pediatric Langerhans cell histiocytosis: Demonstration by allele-specific PCR/direct sequencing and immunohistochemistry

American Journal of Surgical Pathology

Volumn 38, Issue 12, 2014, Pages 1644-1648

  Méhes, Gábor ^a   Irsai, Gábor ^a   Bedekovics, Judit ^a   Beke, Lívia ^a   Fazakas, Ferenc ^a   Rózsa, Tímea ^a   Kiss, Csongor ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

BRAF mutation; Childhood cancer; Histiocytosis; Molecular pathology; Prognosis; Vemurafenib

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN;

ADOLESCENT; ALLELE; CHILD; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; LANGERHANS CELL HISTIOCYTOSIS; MALE; MUTATION; NEWBORN; NUCLEOTIDE SEQUENCE; PRESCHOOL CHILD; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY;

ADOLESCENT; ALLELES; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; FEMALE; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; INFANT, NEWBORN; MALE; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES;

EID: 84914682992     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000304     Document Type: Article

References (31)

1. Jaffe R, Weiss LM, Facchetti F. Tumours derived from Langerhans cells. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer; 2008:358-360.
2. Satter EK, High WA. Langerhans cell histiocytosis: a review of the current recommendations of the Histiocyte Society. Pediatr Dermatol. 2008;25:291-295.
3. Badalian-Very G, Vergilio JA, Degar BA, et al. Recent advances in the understanding of Langerhans cell histiocytosis. Br J Haematol. 2011;156:163-172.
4. Garabedian L, Struyf S, Opdenakker G, et al. Langerhans cell histiocytosis: a cytokine/chemokine-mediated disorder? Eur Cytokine Netw. 2011;22:148-153.
5. Gong L, Zhang WD, Li YH, et al. Clonal status and clinicopathological features of Langerhans cell histiocytosis. J Int Med Res. 2010;38:1099-1105.
6. Allen CE, Li L, Peters TL, et al. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared to epidermal Langerhans cells. J Immunol. 2010;184:4557-4567.
7. Minkov M. Multisystem Langerhans cell histiocytosis in children. Pediatr Drugs. 2011;13:75-86.
8. Colombino M, Capone M, Lissia A, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol. 2012;30:2522-2529.
9. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600E mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707-714.
10. Minoo P, Moyer MP, Jass JR. Role of BRAF-V600E in the serrated pathway of colorectal tumorigenesis. J Pathol. 2007;212:124-133.
11. Farina-Sarasqueta A, Van Lijnschoten G, Moerland E, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol. 2010;21:2396-2402.
12. Grisham RN, Iyer G, Garg K, et al. BRAF mutation is associated with early stage disease and improved outcome in patients with lowgrade serous ovarian cancer. Cancer. 2013;119:548-554.
13. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88:5399-5404.
14. Kim TH, Park YJ, Lim JA, et al. The association of the BRAF V600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer. Cancer. 2011;118:1764-1773.
15. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy cell leukemia. N Engl J Med. 2011;364:2305-2315.
16. Tiacci E, Schiavoni G, Forconi F, et al. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood. 2012;119:192-195.
17. Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116:1919-1923.
18. Satoh T, Smith A, Sarde A, et al. B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease. PLoS One. 2012;7:e33891.
19. Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytes. Blood. 2012;120:2700-2703.
20. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 2011;122:11-19.
21. Rössle M, Sigg M, Rüschoff JH, et al. Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma. Virchows Arch. 2013;463:623-631.
22. Long GV, Wilmott JS, Capper D, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol. 2013;37:61-65.
23. Koperek O, Kornauth C, Capper D, et al. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol. 2012;36:844-850.
24. Zimmermann AK, Camenisch U, Rechsteiner MP, et al. Value of immunohistochemistry in the detection of BRAF V600E mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma. Cancer Cytopathol. 2014;122:48-58.
25. Ihle MA, Fassunke J, König K, et al. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p. V600E and non-p. V600E BRAF mutations. BMC Cancer. 2014;14:13.
26. Bösmüller H, Fischer A, Pham DL, et al. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with mutation specific monoclonal antibody and allele-specific PCR. Hum Pathol. 2013;44:329-335.
27. Donadieu J, Chalard F, Jeziorski E. Medical management of Langerhans cell histiocytosis from diagnosis to treatment. Expert Opin Pharmacother. 2012;13:1309-1322.
28. Haroche J, Cohen-Aubart F, Emile JF, et al. Dramatic effect in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013;121:1495-1500.
29. Ravnan MC, Matalka MS. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. Clin Ther. 2012;34:1474-1486.
30. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAFmutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358-365.
31. Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR. Nature. 2012;483:100-103.